Skip to main content
. 2020 Dec 3;11:605185. doi: 10.3389/fphar.2020.605185

TABLE 3.

Clinical trial design.

CT phase No. CTs (%) No. randomized CTs (total no. 71) (92%) Standard arm placebo Standard arm control Standard arm other drug
Phase 1 1 (1.3) 1 (1.3) 0 0 1 (1.3)
Phase 2 12 (15.6) 9 (11.7) 2 (2.6) 5 (6.5) 2 (2.6)
Phase 3–2/3 53 (68.8) 53 (68.8) 26 (33.8) 15 (19.5) 12 (15.6)
Phase 4 4 (5.2) 4 (5.2) 4 (5.2) 0 0
NA/UN 7 (9.1) 4 (5.2) 1 (1.3) 2 (2.6) 1 (1.3)

CT, clinical trial; NA, not applicable; UN, unknown.